Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 322

1.

Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.

Chiosis G, Caldas Lopes E, Solit D.

Curr Opin Investig Drugs. 2006 Jun;7(6):534-41. Review.

PMID:
16784024
2.
3.

Emerging Hsp90 inhibitors: from discovery to clinic.

Chiosis G, Rodina A, Moulick K.

Anticancer Agents Med Chem. 2006 Jan;6(1):1-8. Review.

PMID:
16475922
4.

Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.

Stravopodis DJ, Margaritis LH, Voutsinas GE.

Curr Med Chem. 2007;14(29):3122-38. Review.

PMID:
18220746
5.

[Heat shock protein 90: novel target for cancer therapy].

Chen Y, Ding J.

Ai Zheng. 2004 Aug;23(8):968-74. Review. Chinese.

PMID:
15301726
6.

Hsp90 inhibitors as novel cancer chemotherapeutic agents.

Neckers L.

Trends Mol Med. 2002;8(4 Suppl):S55-61. Review.

PMID:
11927289
7.

Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.

Moser C, Lang SA, Stoeltzing O.

Anticancer Res. 2009 Jun;29(6):2031-42. Review.

8.

[Molecular chaperone HSP90 as a novel target for cancer chemotherapy].

Miyata Y.

Nihon Yakurigaku Zasshi. 2003 Jan;121(1):33-42. Review. Japanese.

PMID:
12617036
9.

Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent.

Hanson BE, Vesole DH.

Expert Opin Investig Drugs. 2009 Sep;18(9):1375-83. doi: 10.1517/13543780903158934. Review.

PMID:
19642950
10.

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.

Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ.

Nature. 2003 Sep 25;425(6956):407-10.

11.

Geldanamycin and its anti-cancer activities.

Fukuyo Y, Hunt CR, Horikoshi N.

Cancer Lett. 2010 Apr 1;290(1):24-35. doi: 10.1016/j.canlet.2009.07.010. Epub 2009 Oct 21. Review.

PMID:
19850405
12.

Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.

Powers MV, Workman P.

Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S125-35. Review.

13.

The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation.

Grenert JP, Sullivan WP, Fadden P, Haystead TA, Clark J, Mimnaugh E, Krutzsch H, Ochel HJ, Schulte TW, Sausville E, Neckers LM, Toft DO.

J Biol Chem. 1997 Sep 19;272(38):23843-50.

14.

Cancer: the rules of attraction.

Neckers L, Lee YS.

Nature. 2003 Sep 25;425(6956):357-9. No abstract available.

PMID:
14508471
15.

Purine-scaffold Hsp90 inhibitors.

Chiosis G, Tao H.

IDrugs. 2006 Nov;9(11):778-82.

PMID:
17096299
16.

Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.

Le Brazidec JY, Kamal A, Busch D, Thao L, Zhang L, Timony G, Grecko R, Trent K, Lough R, Salazar T, Khan S, Burrows F, Boehm MF.

J Med Chem. 2004 Jul 15;47(15):3865-73.

PMID:
15239664
17.
18.

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.

Lundgren K, Zhang H, Brekken J, Huser N, Powell RE, Timple N, Busch DJ, Neely L, Sensintaffar JL, Yang YC, McKenzie A, Friedman J, Scannevin R, Kamal A, Hong K, Kasibhatla SR, Boehm MF, Burrows FJ.

Mol Cancer Ther. 2009 Apr;8(4):921-9. doi: 10.1158/1535-7163.MCT-08-0758.

19.

Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.

Ochel HJ, Eichhorn K, Gademann G.

Cell Stress Chaperones. 2001 Apr;6(2):105-12. Review. No abstract available. Erratum in: Cell Stress Chaperones 2001 Jul;6(3):295.

20.

Hsp90: the vulnerable chaperone.

Chiosis G, Vilenchik M, Kim J, Solit D.

Drug Discov Today. 2004 Oct 15;9(20):881-8. Review.

PMID:
15475321

Supplemental Content

Support Center